Abstract
Structure based design has been widely used in many drug development programs. In parallel with the evolution of high performance computing systems and versatile molecular modeling programs, structure based drug design has become indispensible in many research areas. CYP51 is a proven therapeutic target for anti-fungal drugs. While anti-fungal drugs targeting CYP51 have a long history and a large pool of anti-fungal CYP51 inhibitor therapeutics are now available, structure based design of therapeutic agents targeting CYP51 has only recently been attempted, Here, we present structural features of CYP51 and its complexes formed with lanosterol, azole drugs, and specifically designed inhibitors. In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes. It is anticipated that comparative analyses of these structures, and other structures that emerge in coming years, will provide clear rationales to address issues in the development of CYP51 drug candidates such as drug resistant, selectivity against other human CYP enzymes, and diversity of CYP51 inhibitors.
Keywords: Anti-fungal azole drugs, Anti-parasitic agents, Computer guided drug design, CYP51, Infectious disease, Structure based drug design.
Current Topics in Medicinal Chemistry
Title:Structure Based Design of CYP51 Inhibitors
Volume: 17 Issue: 1
Author(s): Jun Yong Choi and William R. Roush
Affiliation:
Keywords: Anti-fungal azole drugs, Anti-parasitic agents, Computer guided drug design, CYP51, Infectious disease, Structure based drug design.
Abstract: Structure based design has been widely used in many drug development programs. In parallel with the evolution of high performance computing systems and versatile molecular modeling programs, structure based drug design has become indispensible in many research areas. CYP51 is a proven therapeutic target for anti-fungal drugs. While anti-fungal drugs targeting CYP51 have a long history and a large pool of anti-fungal CYP51 inhibitor therapeutics are now available, structure based design of therapeutic agents targeting CYP51 has only recently been attempted, Here, we present structural features of CYP51 and its complexes formed with lanosterol, azole drugs, and specifically designed inhibitors. In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes. It is anticipated that comparative analyses of these structures, and other structures that emerge in coming years, will provide clear rationales to address issues in the development of CYP51 drug candidates such as drug resistant, selectivity against other human CYP enzymes, and diversity of CYP51 inhibitors.
Export Options
About this article
Cite this article as:
Choi Yong Jun and Roush R. William, Structure Based Design of CYP51 Inhibitors, Current Topics in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1568026616666160719164933
DOI https://dx.doi.org/10.2174/1568026616666160719164933 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies IL-10 Promoter -592 Polymorphism may Influence Susceptibility to HIV Infection in South Indian Population
Current HIV Research Designing Type II Topoisomerase Inhibitors: A Molecular Modeling Approach
Current Topics in Medicinal Chemistry Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design The TLR4 ASP299GLY Polymorphism is a Risk Factor for Active Tuberculosis in Caucasian HIV-Infected Patients
Current HIV Research Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients
Current HIV Research Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology CAPi: Computational Model for Apicoplast Inhibitors Prediction Against Plasmodium Parasite
Current Computer-Aided Drug Design Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Antimicrobial Compounds from Marine Invertebrates-Derived Microorganisms
Current Medicinal Chemistry Synthesis and Biological Evaluation of Triazole-Vanillin Molecular Hybrids as Anti-Cancer Agents
Current Bioactive Compounds Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Phytochemistry, Antinociceptive and Anti-inflammatory Actvities of Methanolic Leaves Extract of Lannea schimperi (Hoschst. Ex Rich) ENG.
Recent Patents on Biotechnology Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry Antibacterial and Antibiofilm Potentials of Marine Pyrrole-2-Aminoimidazole Alkaloids and their Synthetic Analogs
Mini-Reviews in Medicinal Chemistry Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism